
## Jeptha P Curtis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5684526/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The bleeding risk treatment paradox at the physician and hospital level: Implications for reducing bleeding in patients undergoing percutaneous coronary intervention. American Heart Journal, 2022, 243, 221-231.	1.2	2
2	Estimation of DAPT Study Treatment Effects in Contemporary Clinical Practice: Findings From the EXTEND-DAPT Study. Circulation, 2022, 145, 97-106.	1.6	20
3	Changes in left atrial appendage orifice following percutaneous left atrial appendage closure using three-dimensional echocardiography. International Journal of Cardiovascular Imaging, 2022, 38, 1361-1369.	0.7	1
4	Risk and predictors of mortality after implantable cardioverter-defibrillator implantation in patients with sarcoid cardiomyopathy. American Heart Journal, 2022, 246, 21-31.	1.2	6
5	Hospital Characteristics and Early Enrollment Trends in the American College of Cardiology Voluntary Public Reporting Program. JAMA Network Open, 2022, 5, e2147903.	2.8	0
6	Longitudinal Outcomes of Subcutaneous or Transvenous Implantable Cardioverter-Defibrillators in Older Patients. Journal of the American College of Cardiology, 2022, 79, 1050-1059.	1.2	9
7	Trends in Use of Single- vs Dual-Chamber Implantable Cardioverter-Defibrillators Among Patients Without a Pacing Indication, 2010-2018. JAMA Network Open, 2022, 5, e223429.	2.8	3
8	Clinical Impact of Residual Leaks Following Left Atrial Appendage Occlusion. JACC: Clinical Electrophysiology, 2022, 8, 766-778.	1.3	54
9	Clinical Outcomes at 1 Year Following Transcatheter Left Atrial Appendage Occlusion in the United States. JACC: Cardiovascular Interventions, 2022, 15, 741-750.	1.1	19
10	Periprocedural Pericardial Effusion Complicating Transcatheter Left Atrial Appendage Occlusion: A Report From the NCDR LAAO Registry. Circulation: Cardiovascular Interventions, 2022, 15, .	1.4	14
11	The National Cardiovascular Data Registry Data Quality Program 2020. Journal of the American College of Cardiology, 2022, 79, 1704-1712.	1.2	15
12	Patient-Level Analysis of Watchman Left Atrial Appendage Occlusion in Practice Versus Clinical Trials. JACC: Cardiovascular Interventions, 2022, 15, 950-961.	1.1	11
13	Antithrombotic Therapy After LeftÂAtrialÂAppendage Occlusion in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2022, 79, 1785-1798.	1.2	42
14	Survival Probability and Survival Benefit Associated With Primary Prevention Implantable Cardioverterâ€Defibrillator Generator Changes. Journal of the American Heart Association, 2022, 11, .	1.6	2
15	Temporal Changes and Institutional Variation in Use of Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction With Multivessel Coronary Artery Disease in the United States. JAMA Cardiology, 2021, 6, 574.	3.0	9
16	Paclitaxel-coated devices in the treatment of femoropopliteal stenosis among patients ≥65 years old: An ACC PVI Registry Analysis. American Heart Journal, 2021, 233, 59-67.	1.2	4
17	Characteristics of cardiac catheterization laboratory directors at the 2017 U.S. News & World Report top 100 U.S. cardiovascular hospitals. Catheterization and Cardiovascular Interventions, 2021, 97, E624-E626.	0.7	0
18	Use and Outcomes of Dual Chamber or Cardiac Resynchronization Therapy Defibrillators Among Older Patients Requiring Ventricular Pacing in the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator Registry. JAMA Network Open, 2021, 4, e2035470.	2.8	0

#	Article	IF	CITATIONS
19	Comparability of Event Adjudication Versus Administrative Billing Claims for Outcome Ascertainment in the DAPT Study. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e006589.	0.9	20
20	Use of Mechanical Circulatory Support Devices Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock. JAMA Network Open, 2021, 4, e2037748.	2.8	54
21	Variation in propofol induction doses administered to surgical patients over age 65. Journal of the American Geriatrics Society, 2021, 69, 2195-2209.	1.3	11
22	Impact of insurance status on ICD implantation practice patterns: Insights from the NCDR ICD registry. American Heart Journal, 2021, 235, 44-53.	1.2	5
23	Association of COVID-19 Hospitalization Volume and Case Growth at US Hospitals with Patient Outcomes. American Journal of Medicine, 2021, 134, 1380-1388.e3.	0.6	9
24	Predicting In-Hospital Mortality in Patients Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2021, 78, 216-229.	1.2	36
25	Sex Differences in Procedural Outcomes Among Patients Undergoing Left Atrial Appendage Occlusion. JAMA Cardiology, 2021, 6, 1275.	3.0	49
26	Comparative Outcomes of Percutaneous Coronary Intervention for ST-Segment–Elevation Myocardial Infarction Among Medicare Beneficiaries With Multivessel Coronary Artery Disease: An National Cardiovascular Data Registry Research to Practice Project. Circulation: Cardiovascular Interventions, 2021, 14, e010323.	1.4	4
27	Comparative outcomes of Riata and Fidelis lead management strategies: Results from the NCDRâ€lCD Registry. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 1897-1906.	0.5	3
28	Longitudinal Outcomes Associated With Non-Evidence-Based Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries (From the National Cardiovascular Data Registry). American Journal of Cardiology, 2021, 155, 64-71.	0.7	1
29	Defibrillation Safety Margin Testing in Patients With Congenital Heart Disease. JACC: Clinical Electrophysiology, 2021, 7, 1145-1154.	1.3	2
30	Trends in ICD Implantations and In-Hospital Outcomes after DOJ Investigation. Journal of Cardiac Failure, 2021, , .	0.7	0
31	Comparison of Patients Undergoing Percutaneous Coronary Intervention in Contemporary U.S.APractice With ISCHEMIA Trial Population. JACC: Cardiovascular Interventions, 2021, 14, 2344-2349.	1.1	11
32	Myocardial infarction with non-obstructive coronary arteries as compared with myocardial infarction and obstructive coronary disease: outcomes in a Medicare population. European Heart Journal, 2020, 41, 870-878.	1.0	76
33	Association of body mass index with cardiac resynchronization therapy intention and left ventricular lead implantation failure: insights from the NCDR implantable cardioverter-defibrillator registry. Journal of Interventional Cardiac Electrophysiology, 2020, 57, 279-288.	0.6	1
34	Quadripolar versus bipolar leads in cardiac resynchronization therapy: An analysis of the National Cardiovascular Data Registry. Heart Rhythm, 2020, 17, 81-89.	0.3	5
35	Modeling defibrillation benefit for survival among cardiac resynchronization therapy defibrillator recipients. American Heart Journal, 2020, 222, 93-104.	1.2	4
36	Comparison of Mortality and Readmission in Non-Ischemic Versus Ischemic Cardiomyopathy After Implantable Cardioverter-Defibrillator Implantation. American Journal of Cardiology, 2020, 133, 116-125.	0.7	13

#	Article	IF	CITATIONS
37	Duration of P2Y12 inhibitor Prescription After Percutaneous Coronary Intervention in Patients on Oral Anticoagulants (from NCDR CathPCI Registry). American Journal of Cardiology, 2020, 133, 182-184.	0.7	0
38	Contemporary Trends, Predictors and Outcomes of Perforation During Percutaneous Coronary Intervention (From the NCDR Cath PCI Registry). American Journal of Cardiology, 2020, 130, 37-45.	0.7	16
39	Use of Administrative Claims Data to Estimate Treatment Effects for 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. Circulation, 2020, 142, 306-308.	1.6	8
40	Association Between Industry Payments to Physicians and Device Selection in ICD Implantation. JAMA - Journal of the American Medical Association, 2020, 324, 1755.	3.8	26
41	Revascularization Practices and Outcomes in Patients With Multivessel Coronary Artery Disease Who Presented With Acute Myocardial Infarction and Cardiogenic Shock in the US, 2009-2018. JAMA Internal Medicine, 2020, 180, 1317.	2.6	21
42	Comparison of left ventricular lead upgrade vs continued medical care among patients eligible for cardiac resynchronization therapy at the time of defibrillator generator replacement: Predictors of left ventricular lead upgrade and associations with long-term outcomes. Heart Rhythm, 2020, 17, 1878-1886.	0.3	3
43	Sex Differences in 1â€Year Health Status Following Percutaneous Coronary Intervention in Patients Without Acute Myocardial Infarction: Results From the China PEACE Prospective Study. Journal of the American Heart Association, 2020, 9, e014421.	1.6	3
44	Periprocedural Risk and Survival Associated With Implantable Cardioverter-Defibrillator Placement in Older Patients With Advanced Heart Failure. JAMA Cardiology, 2020, 5, 643-651.	3.0	7
45	Association of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock. JAMA - Journal of the American Medical Association, 2020, 323, 734.	3.8	260
46	Attribution of Adverse Events Following Coronary Stent Placement Identified Using Administrative Claims Data. Journal of the American Heart Association, 2020, 9, e013606.	1.6	10
47	Patient and hospital characteristics associated with ticagrelor uptake in acute MI: An analysis of the Chest Pain–MI Registry. International Journal of Cardiology, 2020, 304, 14-20.	0.8	4
48	Prevalence, predictors and complications with defibrillation threshold testing in pediatric patients: Results from the NCDR. International Journal of Cardiology, 2020, 305, 44-49.	0.8	4
49	The NCDR Left Atrial Appendage Occlusion Registry. Journal of the American College of Cardiology, 2020, 75, 1503-1518.	1.2	237
50	Utilization Effects of the Affordable Care Act on Implantable Cardioverter-Defibrillator Therapy. Journal of the American College of Cardiology, 2020, 75, 1714-1717.	1.2	1
51	Stent selection among patients with chronic kidney disease: Results from the NCDR CathPCI Registry. Catheterization and Cardiovascular Interventions, 2020, 96, 1213-1221.	0.7	2
52	COVID-19 infections and outcomes in a live registry of heart failure patients across an integrated health care system. PLoS ONE, 2020, 15, e0238829.	1.1	21
53	Trends in Use and In-Hospital Outcomes of Subcutaneous Implantable Cardioverter Defibrillators in Patients Undergoing Long-Term Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1622-1630.	2.2	10
54	Title is missing!. , 2020, 15, e0238829.		0

#	Article	IF	CITATIONS
55	Title is missing!. , 2020, 15, e0238829.		Ο
56	Title is missing!. , 2020, 15, e0238829.		0
57	Title is missing!. , 2020, 15, e0238829.		0
58	Comparison of Machine Learning Methods With National Cardiovascular Data Registry Models for Prediction of Risk of Bleeding After Percutaneous Coronary Intervention. JAMA Network Open, 2019, 2, e196835.	2.8	60
59	Body mass index and outcomes of cardiac resynchronization with implantable cardioverterâ€defibrillator therapy in older patients with heart failure. European Journal of Heart Failure, 2019, 21, 1093-1102.	2.9	12
60	Cardiac Resynchronization Defibrillator Therapy for Nonspecific Intraventricular Conduction Delay VersusÂRight Bundle Branch Block. Journal of the American College of Cardiology, 2019, 73, 3082-3099.	1.2	21
61	Analysis of Temporal Trends and Variation in the Use of Defibrillation Testing in Contemporary Practice. JAMA Network Open, 2019, 2, e1913553.	2.8	7
62	Association of Physician Specialty With Long-Term Implantable Cardioverter-Defibrillator Complication and Reoperations Rates. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005374.	0.9	4
63	Distribution of Industry Payments Among Medical Directors of Catheterization and Electrophysiology Laboratories From the Top 100 US Hospitals. JAMA Internal Medicine, 2019, 179, 1282.	2.6	9
64	Acute Kidney Injury Among Older Patients Undergoing Coronary Angiography for Acute Myocardial Infarction: The SILVER-AMI Study. American Journal of Medicine, 2019, 132, e817-e826.	0.6	21
65	Validating the use of registries and claims data to support randomized trials: Rationale and design of the Extending Trial-Based Evaluations of Medical Therapies Using Novel Sources of Data (EXTEND) Study. American Heart Journal, 2019, 212, 64-71.	1.2	23
66	Trends in Performance and Opportunities for Improvement on a Composite Measure of Acute Myocardial Infarction Care. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e004983.	0.9	19
67	Outcomes and costs of remote patient monitoring among patients with implanted cardiac defibrillators: An economic model based on the PREDICT RM database. Journal of Cardiovascular Electrophysiology, 2019, 30, 1066-1077.	0.8	17
68	Institutional Variation in Quality of Cardiovascular Implantable Electronic Device Implantation. Annals of Internal Medicine, 2019, 171, 309.	2.0	32
69	Comparison of Clinical Trials and Administrative Claims to Identify Stroke Among Patients Undergoing Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2019, 12, e008231.	1.4	17
70	Outcomes following implantable cardioverter-defibrillator generator replacement in patients with recovered left ventricular systolic function: The National Cardiovascular Data Registry. Heart Rhythm, 2019, 16, 733-740.	0.3	13
71	Association of Statewide Certificate of Need Regulations With Percutaneous Coronary Intervention Appropriateness and Outcomes. Journal of the American Heart Association, 2019, 8, e010373.	1.6	8
72	Ventricular Fibrillation Conversion Testing After Implantation of a Subcutaneous Implantable Cardioverter Defibrillator. Circulation, 2018, 137, 2463-2477.	1.6	34

#	Article	IF	CITATIONS
73	Incidence and Predictors of Perioperative Complications With Transvenous Lead Extractions. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e004768.	2.1	128
74	Adoption of the transradial approach for percutaneous coronary intervention and rates of vascular complications following transfemoral procedures: Insights from <scp>NCDR</scp> . Catheterization and Cardiovascular Interventions, 2018, 92, 835-841.	0.7	7
75	Comparison of Physician Visual Assessment With Quantitative Coronary Angiography in Assessment of Stenosis Severity in China. JAMA Internal Medicine, 2018, 178, 239.	2.6	34
76	Ventricular septal rupture complicating acute myocardial infarction: Incidence, treatment, and outcomes among medicare beneficiaries 1999–2014. Catheterization and Cardiovascular Interventions, 2018, 92, 1104-1115.	0.7	38
77	Coronary Venous Dissection from Left Ventricular Lead Placement During Cardiac Resynchronization Therapy With Defibrillator Implantation and Associated in-Hospital Adverse Events (from the NCDR ICD) Tj ETQq1	100778432	1 <b>\$</b> rgBT /C
78	Long-term morbidity and mortality after implantable cardioverter-defibrillator implantation with procedural complication: A report from the National Cardiovascular Data Registry. Heart Rhythm, 2018, 15, 847-854.	0.3	12
79	Industry Payments to Cardiologists. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e005016.	0.9	28
80	Predicting Length of Stay and the Need for Postacute Care After Acute Myocardial Infarction to Improve Healthcare Efficiency. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004635.	0.9	18
81	Clinical Model to Predict 90-Day Risk of Readmission After Acute Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004788.	0.9	18
82	Accounting for Nonadherence. Circulation, 2018, 137, 2139-2141.	1.6	0
83	Association of the US Department of Justice Investigation of Implantable Cardioverter-Defibrillators and Devices Not Meeting the Medicare National Coverage Determination, 2007-2015. JAMA - Journal of the American Medical Association, 2018, 320, 63.	3.8	14
84	Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone. Circulation, 2018, 138, 1210-1220.	1.6	42
85	More Than One Way to Close the GenderÂGap. Journal of the American College of Cardiology, 2018, 71, 2133-2135.	1.2	3
86	Use of Cardiac Resynchronization Therapy Among Eligible Patients Receiving an Implantable Cardioverter Defibrillator. JAMA Cardiology, 2017, 2, 561.	3.0	16
87	PCI Appropriateness in New York. Journal of the American College of Cardiology, 2017, 69, 1243-1246.	1.2	7
88	Addition of Blood Pressure and Weight Transmissions to Standard Remote Monitoring of Implantable Defibrillators and its Association with Mortality and Rehospitalization. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	6
89	Temporal Trends in and FactorsÂAssociated With Use of Single-ÂVersusÂDual-Coil Implantable Cardioverter-Defibrillator Leads. JACC: Clinical Electrophysiology, 2017, 3, 612-619.	1.3	10
90	Gender differences in physical activity following acute myocardial infarction in adults: A prospective, observational study. European Journal of Preventive Cardiology, 2017, 24, 192-203.	0.8	47

#	Article	IF	CITATIONS
91	Seattle Heart Failure and Proportional RiskÂModels Predict Benefit From ImplantableÂCardioverter-Defibrillators. Journal of the American College of Cardiology, 2017, 69, 2606-2618.	1.2	79
92	Hospital Performance on Percutaneous Coronary Intervention Process and Outcomes Measures. Journal of the American Heart Association, 2017, 6, .	1.6	11
93	Executive Summary: Trends in U.S. Cardiovascular Care. Journal of the American College of Cardiology, 2017, 69, 1424-1426.	1.2	48
94	Trends in U.S. Cardiovascular Care. Journal of the American College of Cardiology, 2017, 69, 1427-1450.	1.2	198
95	Carotid Endarterectomy and Carotid Artery Stenting in the US Medicare Population, 1999-2014. JAMA - Journal of the American Medical Association, 2017, 318, 1035.	3.8	111
96	Modeling Major Adverse Outcomes of Pediatric and Adult Patients With Congenital Heart Disease Undergoing Cardiac Catheterization. Circulation, 2017, 136, 2009-2019.	1.6	46
97	Complications Associated With Implantable Cardioverter Defibrillators in Adults With Congenital Heart Disease or Left Ventricular Noncompaction Cardiomyopathy (From the NCDR® Implantable) Tj ETQq1 1	0.7 <b>8</b> <del>4</del> 314	rgB219/Overlo
98	Development and validation of a simple risk score to predict 30â€day readmission after percutaneous coronary intervention in a cohort of medicare patients. Catheterization and Cardiovascular Interventions, 2017, 89, 955-963.	0.7	11
99	Can machine learning complement traditional medical device surveillance? A case-study of dual-chamber implantable cardioverter–defibrillators. Medical Devices: Evidence and Research, 2017, Volume 10, 165-188.	0.4	9
100	Impact of Glycoprotein IIb/IIIa Inhibitors Use on Outcomes After Lower Extremity Endovascular Interventions From Nationwide Inpatient Sample (2006–2011). Catheterization and Cardiovascular Interventions, 2016, 88, 605-616.	0.7	2
101	Long-Term Risk for Device-Related Complications and Reoperations After Implantable Cardioverter-Defibrillator Implantation. Annals of Internal Medicine, 2016, 165, 20.	2.0	64
102	Temporal Trends in the Risk Profile of Patients Undergoing Outpatient Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2016, 9, e003070.	1.4	41
103	Response to Letter Regarding Article, "Temporal Trends in Percutaneous Coronary Intervention Appropriateness: Insights From the Clinical Outcomes Assessment Program― Circulation, 2016, 133, e424.	1.6	2
104	Trends and In-Hospital Outcomes Associated With Adoption of the Subcutaneous Implantable Cardioverter Defibrillator in the United States. JAMA Cardiology, 2016, 1, 900.	3.0	127
105	Outcomes 1 Year After Implantable Cardioverter–Defibrillator Lead Abandonment Versus Explantation for Unused or Malfunctioning Leads. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	2.1	25
106	A Fresh Perspective on Atrial Fibrillation â^—. Journal of the American College of Cardiology, 2016, 68, 905-907.	1.2	0
107	Coronary Catheterization and Percutaneous Coronary Intervention in China. JAMA Internal Medicine, 2016, 176, 512.	2.6	72
108	Association of Physician Certification in Interventional Cardiology With In-Hospital Outcomes of Percutaneous Coronary Intervention. Circulation, 2015, 132, 1816-1824.	1.6	13

#	Article	IF	CITATIONS
109	Comparison of Inhospital Outcomes and Hospitalization Costs of Peripheral Angioplasty and Endovascular Stenting. American Journal of Cardiology, 2015, 116, 634-641.	0.7	4
110	Does Age Influence Cardiac Resynchronization Therapy Use andÂOutcome?. JACC: Heart Failure, 2015, 3, 497-504.	1.9	17
111	Comparative Effectiveness of CRT-D Versus Defibrillator Alone in HF Patients With Moderate-to-Severe Chronic Kidney Disease. Journal of the American College of Cardiology, 2015, 66, 2618-2629.	1.2	26
112	Effect of Hospital Volume on Outcomes of Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2015, 116, 587-594.	0.7	70
113	Primary Prevention Implantable Cardioverter-Defibrillators and Survival in Older Women. JACC: Heart Failure, 2015, 3, 159-167.	1.9	30
114	Frequency and Effects of Excess Dosing of Anticoagulants in Patients â‰ <b>9</b> 5ÂYears With Acute Myocardial Infarction Who Underwent Percutaneous Coronary Intervention (from the VIRGO Study). American Journal of Cardiology, 2015, 116, 1-7.	0.7	11
115	Hospital Variability in Use of Anticoagulant Strategies During Acute Myocardial Infarction Treated With an Early Invasive Strategy. Journal of the American Heart Association, 2015, 4, e002009.	1.6	2
116	State Mandated Public Reporting and Outcomes of Percutaneous Coronary Intervention in the United States. American Journal of Cardiology, 2015, 115, 1494-1501.	0.7	27
117	Readmissions After Carotid Artery Revascularization in the Medicare Population. Journal of the American College of Cardiology, 2015, 65, 1398-1408.	1.2	26
118	Cardiac Resynchronization Therapy in Women Versus Men. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, S4-11.	0.9	59
119	Antithrombotic Therapy and Outcomes After ICD Implantation in Patients With Atrial Fibrillation and Coronary Artery Disease: An Analysis From the National Cardiovascular Data Registry (NCDR) <sup>®</sup> . Journal of the American Heart Association, 2015, 4, .	1.6	8
120	Use of Remote Monitoring Is Associated With Lower Risk of Adverse Outcomes Among Patients With Implanted Cardiac Defibrillators. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 1173-1180.	2.1	56
121	Impact of Hospital Volume on Outcomes of Lower Extremity Endovascular Interventions (Insights) Tj ETQq1 1 0.	784314 rg 0.7	gBT /Overlo <mark>ck</mark> 28
122	National Trends in Pulmonary Embolism Hospitalization Rates and Outcomes for Adults Aged ≥65ÂYears in the United States (1999 to 2010). American Journal of Cardiology, 2015, 116, 1436-1442.	0.7	57
123	Use of Mechanical Circulatory Support in Patients Undergoing Percutaneous Coronary Intervention. Circulation, 2015, 132, 1243-1251.	1.6	100
124	A validated risk model for 1-year mortality after primary prevention implantable cardioverter defibrillator placement. American Heart Journal, 2015, 170, 281-289.e2.	1.2	18
125	The Variation in Recovery: Role of Gender on Outcomes of Young AMI Patients (VIRGO) Classification System. Circulation, 2015, 132, 1710-1718.	1.6	52
126	Patterns of Institutional Review of Percutaneous Coronary Intervention Appropriateness and the Effect on Quality of Care and Clinical Outcomes. JAMA Internal Medicine, 2015, 175, 1988.	2.6	2

#	Article	IF	CITATIONS
127	Gender and outcomes after primary prevention implantable cardioverter-defibrillator implantation: Findings from the National Cardiovascular Data Registry (NCDR). American Heart Journal, 2015, 170, 330-338.	1.2	72
128	Appropriate Use Criteria for Coronary Revascularization and Trends in Utilization, Patient Selection, and Appropriateness of Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2015, 314, 2045.	3.8	212
129	Procedure timing as a predictor of inhospital adverse outcomes from implantable cardioverter-defibrillator implantation: Insights from the National Cardiovascular Data Registry. American Heart Journal, 2015, 169, 45-52.e3.	1.2	12
130	Percutaneous Coronary Intervention Utilization and Appropriateness across the United States. PLoS ONE, 2015, 10, e0138251.	1.1	13
131	Patterns and Outcomes of Red Blood Cell Transfusion in Patients Undergoing Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2014, 311, 836.	3.8	72
132	Implant and Clinical Characteristics for Pediatric and Congenital Heart Patients in the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator Registry. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 1092-1100.	2.1	38
133	Clinical Effectiveness of Cardiac Resynchronization Therapy Versus Medical Therapy Alone Among Patients With Heart Failure. Circulation: Heart Failure, 2014, 7, 926-934.	1.6	20
134	Coronary Artery Bypass Graft Surgery Versus Drug-Eluting Stents for Patients With Isolated Proximal Left Anterior Descending Disease. Journal of the American College of Cardiology, 2014, 64, 2717-2726.	1.2	56
135	In-Hospital Switching Between Clopidogrel and Prasugrel Among Patients With Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2014, 7, 585-593.	1.4	49
136	Living in the Readmission Era. Circulation: Cardiovascular Interventions, 2014, 7, 9-10.	1.4	3
137	Clinical Prediction Model Suitable for Assessing Hospital Quality for Patients Undergoing Carotid Endarterectomy. Journal of the American Heart Association, 2014, 3, e000728.	1.6	11
138	Payments for Acute Myocardial Infarction Episodes-of-Care Initiated at Hospitals With and Without Interventional Capabilities. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 882-888.	0.9	4
139	Change in Hospital-Level Use of Transradial Percutaneous Coronary Intervention and Periprocedural Outcomes. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 550-559.	0.9	47
140	Comparison of Intermediate-Term Outcomes of Coronary Artery Bypass Grafting Versus Drug-Eluting Stents for Patients ≥75ÂYears of Age. American Journal of Cardiology, 2014, 113, 803-808.	0.7	26
141	Survival After Primary Prevention Implantable Cardioverter-Defibrillator Placement Among Patients With Chronic Kidney Disease. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 793-799.	2.1	45
142	Predictors of an Inadequate Defibrillation Safety Margin at ICD Implantation. Journal of the American College of Cardiology, 2014, 64, 256-264.	1.2	32
143	Temporal Trends in Patient Characteristics and Outcomes Among Medicare Beneficiaries Undergoing Primary Prevention Implantable Cardioverter-Defibrillator Placement in the United States, 2006–2010. Circulation, 2014, 130, 845-853.	1.6	32
144	Rates of and Factors Associated With Infection in 200 909 Medicare Implantable Cardioverter-Defibrillator Implants. Circulation, 2014, 130, 1037-1043.	1.6	160

#	Article	IF	CITATIONS
145	Sex-Specific Mortality Risk by QRS Morphology and Duration in Patients Receiving CRT. Journal of the American College of Cardiology, 2014, 64, 887-894.	1.2	85
146	Age and sex differences in inhospital complication rates and mortality after percutaneous coronary intervention procedures: Evidence from the NCDR®. American Heart Journal, 2014, 167, 376-383.	1.2	76
147	Prevalence of Guideline-Directed Medical Therapy Among Patients Receiving Cardiac Resynchronization Therapy Defibrillator Implantation in the National Cardiovascular Data Registry During the Years 2006 to 2008. American Journal of Cardiology, 2014, 113, 2052-2056.	0.7	13
148	Developing a Risk Model for In-Hospital Adverse Events Following Implantable Cardioverter-Defibrillator Implantation. Journal of the American College of Cardiology, 2014, 63, 788-796.	1.2	37
149	Prevalence, Correlates, and Temporal Trends in Antiarrhythmic Drug Use at Discharge After Implantable Cardioverter Defibrillator Placement (from the National Cardiovascular Data Registry) Tj ETQq1 1 0.7	′8 <b>4</b> 3114 rgl	3T1/Dverlock
150	In-Hospital Complications Associated With Reoperations of Implantable Cardioverter Defibrillators. American Journal of Cardiology, 2014, 114, 419-426.	0.7	13
151	Transfer Rates From Nonprocedure Hospitals After Initial Admission and Outcomes Among Elderly Patients With Acute Myocardial Infarction. JAMA Internal Medicine, 2014, 174, 213.	2.6	17
152	Door-to-Balloon Time and Mortality among Patients Undergoing Primary PCI. New England Journal of Medicine, 2013, 369, 901-909.	13.9	609
153	Cardiovascular Care Facts. Journal of the American College of Cardiology, 2013, 62, 1931-1947.	1.2	135
154	Variation among hospitals in selection of higher-cost, "higher-tech,―implantable cardioverter-defibrillators: Data from the National Cardiovascular Data Registry (NCDR) Implantable Cardioverter/Defibrillator (ICD) Registry. American Heart Journal, 2013, 165, 1015-1023.e2.	1.2	13
155	The Prevalence and Outcomes of Transradial Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2013, 61, 420-426.	1.2	149
156	Baby or Bathwater?. Circulation, 2013, 128, 1177-1178.	1.6	2
157	Safety of Pacemaker Implantation in Nonagenarians. Circulation, 2013, 127, 1453-1465.	1.6	32
158	Physician Procedure Volume and Complications of Cardioverter-Defibrillator Implantation. Circulation, 2012, 125, 57-64.	1.6	94
159	Use and Effectiveness of Intra-Aortic Balloon Pumps Among Patients Undergoing High Risk Percutaneous Coronary Intervention: Insights From the National Cardiovascular Data Registry. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 21-30.	0.9	68
160	Development of 2 Registry-Based Risk Models Suitable for Characterizing Hospital Performance on 30-Day All-Cause Mortality Rates Among Patients Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 628-637.	0.9	11
161	Variation in Use of Dual-Chamber Implantable Cardioverter-Defibrillators. Archives of Internal Medicine, 2012, 172, 634.	4.3	34
162	Factors Associated With 30-Day Readmission Rates After Percutaneous Coronary Intervention. Archives of Internal Medicine, 2012, 172, 112.	4.3	98

#	Article	IF	CITATIONS
163	The National Cardiovascular Data Registry (NCDR) Data Quality Brief. Journal of the American College of Cardiology, 2012, 60, 1484-1488.	1.2	324
164	Non–Evidence-Based ICD Implantations in the United States. JAMA - Journal of the American Medical Association, 2011, 305, 43.	3.8	207
165	Operator Experience and Carotid Stenting Outcomes in Medicare Beneficiaries. JAMA - Journal of the American Medical Association, 2011, 306, 1338.	3.8	158
166	Age Differences in Primary Prevention Implantable Cardioverterâ€Defibrillator Use in U.S. Individuals. Journal of the American Geriatrics Society, 2011, 59, 1589-1595.	1.3	8
167	Influence of Age on Perioperative Complications Among Patients Undergoing Implantable Cardioverter-Defibrillators for Primary Prevention in the United States. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 549-556.	0.9	45
168	Regional Variation in the Use of Implantable Cardioverter-Defibrillators for Primary Prevention. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 114-121.	0.9	44
169	Implantable Cardioverter-Defibrillator Registry Risk Score Models for Acute Procedural Complications or Death After Implantable Cardioverter-Defibrillator Implantation. Circulation, 2011, 123, 2069-2076.	1.6	79
170	Recent National Trends in Readmission Rates After Heart Failure Hospitalization. Circulation: Heart Failure, 2010, 3, 97-103.	1.6	373
171	Review of the Registry's Fourth Year, Incorporating Lead Data and Pediatric ICD Procedures, and Use as a National Performance Measure. Heart Rhythm, 2010, 7, 1340-1345.	0.3	146
172	Prevalence and Predictors of Off-Label Use of Cardiac Resynchronization Therapy in Patients Enrolled in the National Cardiovascular Data Registry Implantable Cardiac-Defibrillator Registry. Journal of the American College of Cardiology, 2010, 56, 766-773.	1.2	39
173	The Relation Between Hospital Procedure Volume and Complications of Cardioverter-Defibrillator Implantation From the Implantable Cardioverter-Defibrillator Registry. Journal of the American College of Cardiology, 2010, 56, 1133-1139.	1.2	74
174	All-Cause Readmission and Repeat Revascularization After Percutaneous Coronary Intervention in a Cohort of Medicare Patients. Journal of the American College of Cardiology, 2009, 54, 903-907.	1.2	134
175	Review of the ICD Registry's Third Year, Expansion to include Lead Data and Pediatric ICD Procedures, and Role for Measuring Performance. Heart Rhythm, 2009, 6, 1397-1401.	0.3	81
176	Association of Physician Certification and Outcomes Among Patients Receiving an Implantable Cardioverter-Defibrillator. JAMA - Journal of the American Medical Association, 2009, 301, 1661.	3.8	161
177	Review of the Registry's Second Year, Data Collected, and Plans to Add Lead and Pediatric ICD Procedures. Heart Rhythm, 2008, 5, 1359-1363.	0.3	71
178	The Pre-Hospital Electrocardiogram and Time to Reperfusion in Patients With Acute Myocardial Infarction, 2000–2002. Journal of the American College of Cardiology, 2006, 47, 1544-1552.	1.2	189
179	The Obesity Paradox. Archives of Internal Medicine, 2005, 165, 55.	4.3	702
180	The Prognostic Value of Vasodilator Myocardial Perfusion Imaging in Octogenarians. The American Journal of Geriatric Cardiology, 2004, 13, 239-245.	0.7	11

#	Article	IF	CITATIONS
181	Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic) Tj ETQq1 1 0.78	34 <b>6.1</b> ∕4 rgB <sup>-</sup>	T ⊉Øverlock
182	The association of 6-minute walk performance and outcomes in stable outpatients with heart failure. Journal of Cardiac Failure, 2004, 10, 9-14.	0.7	15
183	The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure. Journal of the American College of Cardiology, 2003, 42, 736-742.	1.2	445
184	Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study. BMJ: British Medical Journal, 2003, 327, 1322-1323.	2.4	75